These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 16607967)
1. Genital herpes vaccines--cause for cautious optimism. Haddow LJ; Mindel A Sex Health; 2006 Mar; 3(1):1-4. PubMed ID: 16607967 [TBL] [Abstract][Full Text] [Related]
2. [Vaccines as an approach to the immunocorrection in herpetic infections]. Barinskiĭ IF; Alimbarova LM; Lazarenko AA; Makhmudov FR; Sergeev OV Vopr Virusol; 2014; 59(1):5-11. PubMed ID: 25065139 [TBL] [Abstract][Full Text] [Related]
3. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology. Sandgren KJ; Truong NR; Smith JB; Bertram K; Cunningham AL Methods Mol Biol; 2020; 2060():31-56. PubMed ID: 31617171 [TBL] [Abstract][Full Text] [Related]
4. An update on short-course episodic and prevention therapies for herpes genitalis. Corey L; Bodsworth N; Mindel A; Patel R; Schacker T; Stanberry L Herpes; 2007 Jun; 14 Suppl 1():5A-11A. PubMed ID: 17877886 [TBL] [Abstract][Full Text] [Related]
5. Current status and prospects for development of an HSV vaccine. Johnston C; Koelle DM; Wald A Vaccine; 2014 Mar; 32(14):1553-60. PubMed ID: 24016811 [TBL] [Abstract][Full Text] [Related]
6. Use of the Guinea pig model of genital herpes to evaluate vaccines and antivirals: Review. Bernstein DI Antiviral Res; 2020 Aug; 180():104821. PubMed ID: 32544409 [TBL] [Abstract][Full Text] [Related]
7. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. Chiuppesi F; Vannucci L; De Luca A; Lai M; Matteoli B; Freer G; Manservigi R; Ceccherini-Nelli L; Maggi F; Bendinelli M; Pistello M J Virol; 2012 Jun; 86(12):6563-74. PubMed ID: 22491465 [TBL] [Abstract][Full Text] [Related]
8. Development of prophylactic vaccines for genital and neonatal herpes. Jones CA; Cunningham AL Expert Rev Vaccines; 2003 Aug; 2(4):541-9. PubMed ID: 14711338 [TBL] [Abstract][Full Text] [Related]
9. Vaccine value profile for herpes simplex virus. Johnston C; Scheele S; Bachmann L; Boily MC; Chaiyakunapruk N; Deal C; Delany-Moretlwe S; Lee S; Looker K; Marshall C; Mello MB; Ndowa F; Gottlieb S Vaccine; 2024 Jul; 42(19S1):S82-S100. PubMed ID: 39003018 [TBL] [Abstract][Full Text] [Related]
10. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine. Samandary S; Kridane-Miledi H; Sandoval JS; Choudhury Z; Langa-Vives F; Spencer D; Chentoufi AA; Lemonnier FA; BenMohamed L Hum Immunol; 2014 Aug; 75(8):715-29. PubMed ID: 24798939 [TBL] [Abstract][Full Text] [Related]
12. Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017. Gottlieb SL; Giersing BK; Hickling J; Jones R; Deal C; Kaslow DC; Vaccine; 2019 Nov; 37(50):7408-7418. PubMed ID: 29224963 [TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial. Gorfinkel IS; Aoki F; McNeil S; Dionne M; Shafran SD; Zickler P; Halperin S; Langley J; Bellamy A; Schulte J; Heineman T; Belshe R Int J STD AIDS; 2013 May; 24(5):345-9. PubMed ID: 23970700 [TBL] [Abstract][Full Text] [Related]
14. Effect of an immune enhancer, GPI-0100, on vaccination with live attenuated herpes simplex virus (HSV) type 2 or glycoprotein D on genital HSV-2 infections of guinea pigs. Quenelle DC; Collins DJ; Rice TL; Prichard MN; Marciani DJ; Kern ER Antiviral Res; 2008 Nov; 80(2):223-4. PubMed ID: 18573279 [TBL] [Abstract][Full Text] [Related]
15. The challenge of developing a herpes simplex virus 2 vaccine. Dropulic LK; Cohen JI Expert Rev Vaccines; 2012 Dec; 11(12):1429-40. PubMed ID: 23252387 [TBL] [Abstract][Full Text] [Related]
16. A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes. Awasthi S; Friedman HM J Infect Dis; 2014 Mar; 209(6):813-5. PubMed ID: 24285847 [No Abstract] [Full Text] [Related]
17. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes. Bernstein DI; Pullum DA; Cardin RD; Bravo FJ; Dixon DA; Kousoulas KG Vaccine; 2019 Jan; 37(1):61-68. PubMed ID: 30471955 [TBL] [Abstract][Full Text] [Related]
18. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Jones CA; Cunningham AL Herpes; 2004 Apr; 11(1):12-7. PubMed ID: 15115632 [TBL] [Abstract][Full Text] [Related]
19. [Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes]. Barinskiĭ IF; Makhmudov FR Vopr Virusol; 2010; 55(1):35-40. PubMed ID: 20364670 [TBL] [Abstract][Full Text] [Related]
20. Correlation between herpes simplex virus neutralizing antibody titers determined by ELVIS cell and traditional plaque reduction assays. Blevins TP; Yu Y; Belshe RB; Bellamy AR; Morrison LA PLoS One; 2019; 14(4):e0214467. PubMed ID: 30946751 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]